(Q44507318)

3 December 2017

title

Balancing the benefits and risks of disease-modifying therapy in patients with multiple sclerosis (English)

1 reference

3 December 2017

0 references

Per Soelberg Sørensen

series ordinal

1

object named as

Per Soelberg Sørensen

1 reference

3 December 2017

publication date

1 December 2011

1 reference

Journal of the Neurological Sciences

3 December 2017

published in

1 reference

3 December 2017

volume

311 Suppl 1

1 reference

3 December 2017

page(s)

S29-34

1 reference

Interferon-beta: mechanism of action and dosing issues

3 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2811%2970006-5

Mechanisms of action of glatiramer acetate in multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2811%2970006-5

Glatiramer acetate: mechanisms of action in multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2811%2970006-5

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2811%2970006-5

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2811%2970006-5

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2811%2970006-5

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2811%2970006-5

Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2811%2970006-5

Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2811%2970006-5

250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2811%2970006-5

NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2811%2970006-5

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2811%2970006-5

Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2811%2970006-5

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2811%2970006-5

Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2811%2970006-5

Progressive multifocal leukoencephalopathy in a patient treated with natalizumab

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2811%2970006-5

New cases of progressive multifocal leukoencephalopathy after treatment with natalizumab

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2811%2970006-5

Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2811%2970006-5

Safety profile of Tysabri: international risk management plan.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2811%2970006-5

Mitoxantrone treatment of multiple sclerosis: safety considerations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2811%2970006-5

Mitoxantrone: benefits and risks in multiple sclerosis patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2811%2970006-5

Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2811%2970006-5

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2811%2970006-5

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2811%2970006-5

A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2811%2970006-5

Predicting responders to therapies for multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2811%2970006-5

Breakthrough disease during interferon-[beta] therapy in MS: No signs of impaired biologic response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2811%2970006-5

Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2811%2970006-5

The immunopathology of multiple sclerosis: an overview

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2811%2970006-5

Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2811%2970006-5

Benefit of interferon beta-1a on MSFC progression in secondary progressive MS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2811%2970006-5

Multicentre, randomised, double blind, placebo controlled, phase III study of weekly, low dose, subcutaneous interferon beta-1a in secondary progressive multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2811%2970006-5

Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2811%2970006-5

Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2811%2970006-5

PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2811%2970006-5

Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2811%2970006-5

Predictors of long-term clinical response to interferon beta therapy in relapsing multiple sclerosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2811%2970006-5

Measures in the first year of therapy predict the response to interferon β in MS

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2811%2970006-5

Rationale for early intervention with immunomodulatory treatments

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2811%2970006-5

10.1016/S0022-510X(11)70006-5

7 January 2021

Identifiers

DOI

1 reference

3 December 2017

1 reference